- Home
- BZUN vs CHRS Comparison
BZUN vs CHRS Comparison
Compare BZUN & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BZUN
- CHRS
- Stock Information
- Founded
- BZUN 2007
- CHRS 2010
- Country
- BZUN China
- CHRS United States
- Employees
- BZUN N/A
- CHRS N/A
- Industry
- BZUN Catalog/Specialty Distribution
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BZUN Consumer Discretionary
- CHRS Health Care
- Exchange
- BZUN Nasdaq
- CHRS Nasdaq
- Market Cap
- BZUN 275.9M
- CHRS 159.2M
- IPO Year
- BZUN N/A
- CHRS 2014
- Fundamental
- Price
- BZUN $4.58
- CHRS $1.35
- Analyst Decision
- BZUN Strong Buy
- CHRS Strong Buy
- Analyst Count
- BZUN 1
- CHRS 4
- Target Price
- BZUN $4.20
- CHRS $4.51
- AVG Volume (30 Days)
- BZUN 735.7K
- CHRS 1.2M
- Earning Date
- BZUN 08-28-2025
- CHRS 11-05-2025
- Dividend Yield
- BZUN N/A
- CHRS N/A
- EPS Growth
- BZUN N/A
- CHRS N/A
- EPS
- BZUN N/A
- CHRS 1.55
- Revenue
- BZUN $1,349,630,922.00
- CHRS $272,209,000.00
- Revenue This Year
- BZUN $5.27
- CHRS N/A
- Revenue Next Year
- BZUN $3.46
- CHRS $109.48
- P/E Ratio
- BZUN N/A
- CHRS $0.87
- Revenue Growth
- BZUN 7.73
- CHRS 52.33
- 52 Week Low
- BZUN $2.12
- CHRS $0.66
- 52 Week High
- BZUN $4.88
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- BZUN 70.87
- CHRS 64.99
- Support Level
- BZUN $4.32
- CHRS $1.23
- Resistance Level
- BZUN $4.88
- CHRS $1.40
- Average True Range (ATR)
- BZUN 0.36
- CHRS 0.08
- MACD
- BZUN 0.09
- CHRS -0.00
- Stochastic Oscillator
- BZUN 86.11
- CHRS 72.13
About BZUN Baozun Inc.
Baozun Inc is engaged to provide its customers with end-to-end e-commerce solutions including the sales of apparel, home and electronic products, online store design and setup, visual merchandising and marketing, online store operations, customer services, warehousing and order fulfillment, as well as the holistic brand management, including strategy and tactic positioning, branding and marketing, retail and e-commerce operations, supply chain and logistics, and technology empowerment. It has two operating segments: E-Commerce (encompassing BEC and BZI) and Brand Management (representing BBM). The company generates maximum of its revenue from E-Commerce (encompassing BEC and BZI) segment.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.